Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Abiraterone acetate

Abstract

In April 2011, abiraterone acetate (Zytiga; Centocor Ortho Biotech), in combination with prednisone, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Structure of abiraterone acetate.

References

  1. 1

    Jemal, A. et al. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300 (2010).

    Article  Google Scholar 

  2. 2

    Attard, G., Belldegrun, A. S. & de Bono, J. S. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 96, 1241–1246 (2005).

    Article  Google Scholar 

  3. 3

    Attard, G. & de Bono, J. S. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin. Cancer Res. 17, 3867–3875 (2011).

    CAS  Article  Google Scholar 

  4. 4

    Potter, G. A. et al. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17, 20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 38, 2463–2471 (1995).

    CAS  Article  Google Scholar 

  5. 5

    US Food and Drug Administration. FDA labeling information — Zytiga. FDA website [online], (2011).

  6. 6

    de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

    CAS  Article  Google Scholar 

  7. 7

    Efstathiou, E, & Logothetis, C. J. A new therapy paradigm for prostate cancer founded on clinical observations. Clin. Cancer Res. 16, 1100–1107 (2010).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Ethics declarations

Competing interests

Christopher J. Logothetis has received research support from Johnson & Johnson, Bristol-Myers Squibb and Medivation, and honoraria from Johnson & Johnson and Bristol-Myers Squibb.

Eleni Efstathiou has received research support from Johnson & Johnson, Bristol-Myers Squibb and Medivation, and honoraria from Johnson & Johnson and Bristol-Myers Squibb.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Logothetis, C., Efstathiou, E., Manuguid, F. et al. Abiraterone acetate. Nat Rev Drug Discov 10, 573–574 (2011). https://doi.org/10.1038/nrd3516

Download citation

Further reading

Search

Quick links